Resources
Thalidomide health practitioner evidence form
This form is a template for health practitioners to provide evidence to support an eligible thalidomide survivor (patient) to receive support from the Extraordinary Assistance Fund (EAF) or the Health Care Assistance Fund (HCAF).
Making a claim to the EAF fact sheet
This fact sheet provides information about how participants of the Australian Thalidomide Survivors Support Program can make a claim to the Extraordinary Assistance Fund (EAF). The EAF helps cover the costs of goods and services to assist with activities of daily living.
Making a claim to the HCAF fact sheet
This fact sheet provides information about how participants of the Australian Thalidomide Survivors Support Program can make a claim to the Health Care Assistance Fund (HCAF). The HCAF helps cover out-of-pocket health care expenses incurred as a direct result of thalidomide injuries.
HCAF support categories fact sheet
This fact sheet provides information for participants of the Australian Thalidomide Survivors Support Program about the categories of goods and services which are eligible to be claimed under the Health Care Assistance Fund (HCAF).
LSDPEP 8th meeting agenda – 19 February 2021
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 8th meeting on 19 February 2021.
Review of CGM products – frequently asked questions for suppliers
This fact sheet answers key questions about the review of Continuous Glucose Monitoring (CGM) products provided through the National Diabetes Services Scheme (NDSS).
Review of CGM products – supplier submission form
Suppliers must use this form to make a submission to the Review of CGM products provided through the National Diabetes Services Scheme (NDSS).
Review of CGM products – submission cover sheet
Stakeholder organisations and other interested parties must use this cover sheet to make a submission to the Review of CGM products provided through the National Diabetes Services Scheme (NDSS).
LSDPEP 7th meeting agenda – 22 and 23 October 2020
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 7th meeting on 22 and 23 October 2020.
LSDPEP 6th meeting agenda – 25 and 26 June 2020
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 6th meeting on 25 and 26 June 2020.
LSDPEP 5th meeting agenda – 16 and 17 April 2020
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 5th meeting on 16 and 17 April 2020.
Life Saving Drugs Program – Cerliponase alfa (Brineura®) outcome statement
This document states the outcome of BioMarin's application to include cerliponase alfa on the Life Saving Drugs Program.
Life Saving Drugs Program – Asfotase alfa (Strensiq®) outcome statement
This document states the outcome of Alexion Pharmaceuticals Australasia's application to include asfotase alfa on the Life Saving Drugs Program.
Support for Australia’s thalidomide survivors
Australian Government response to the Senate Community Affairs References Committee inquiry into support for Australia’s thalidomide survivors
National strategic action plan for kidney disease
This Action Plan aims to provide a blueprint for transforming kidney disease in Australia over the next 10 ten years with over 30 actions across 3 priority areas designed to address the most pressing needs in kidney disease.
National Strategic Action Plan for Rare Diseases
The National Strategic Action Plan for Rare Diseases outlines principles and actions to bring about the best possible health and wellbeing outcomes for Australians living with a rare disease.
Life Saving Drugs Program – Hereditary tyrosinaemia (type 1) – Medicines review protocol
This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for hereditary tyrosinaemia (type 1).
Life Saving Drugs Program – Mucopolysaccharidosis type I (MPS I) – Medicines review protocol
This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for MPS I.
Life Saving Drugs Program – Mucopolysaccharidosis type VI (MPS VI) – Medicines review protocol
This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for MPS VI.
MRFF snapshot – Cardiovascular Health Mission
This snapshot shows this Mission at a glance. It includes budgets, early funding priorities and grant timelines, as at November 2019. Researchers and other stakeholders can use it to plan for upcoming opportunities and see how the Mission will be established, expanded and embedded over time.
MRFF snapshot – Clinical Trials Activity
This snapshot shows this initiative at a glance. It includes budgets, early funding priorities and grant timelines, as at November 2019. Researchers and other stakeholders can use it to plan for upcoming opportunities and see how the initiative will be established, expanded and embedded over time.
National Strategic Action Plan for Osteoporosis 2019
The National Strategic Action Plan for Osteoporosis 2019 aims to reduce the impact of this condition in Australia. It outlines priority areas and actions to improve the quality of life of Australians living with osteoporosis.
National Strategic Action Plan for Macular Disease
The National Strategic Action Plan for Macular Disease proposes a national response to macular disease across all levels of government in Australia. It recommends action in 4 major areas.
National Strategic Framework for Chronic Conditions
The National Strategic Framework for Chronic Conditions is the overarching policy document for chronic conditions. It sets the directions and outcomes to help Australians live healthier lives through effective prevention and management of chronic conditions.
Life Saving Drugs Program – Paroxysmal nocturnal haemoglobinuria – Medicines review protocol
This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for paroxysmal nocturnal haemoglobinuria.
Date last updated: